Taro Pharmaceutical (TARO) has released an update.
Sun Pharmaceutical Industries Limited has announced the completion of its merger with Taro Pharmaceutical Industries Ltd., making Taro a wholly-owned subsidiary and private entity. The merger is anticipated to enhance the combined entity’s competitive edge in the generic pharmaceuticals market. Sun Pharma, the majority shareholder of Taro since 2010, aims to leverage the merged strengths to foster growth and success.
For further insights into TARO stock, check out TipRanks’ Stock Analysis page.
